How to Treat Post-Psoriasis Hyperpigmentation: Which Actives Are Safe When Skin Is Already Compromised?

Post-psoriasis hyperpigmentation is post-inflammatory hyperpigmentation (PIH) — flat, darkened patches that remain after psoriasis plaques have resolved, caused by excess melanin triggered by the inflammatory process itself. It is not a sign that anything has gone wrong; board-certified dermatologist Jason Miller, MD, notes it is "often a sign that the condition is being treated or is under control". Even so, research in psoriasis patients has shown PIH can negatively affect self-reported quality of life, contributing to depression and lower confidence — making it a legitimate medical concern, not merely a cosmetic one.

The frustrating reality is that even when itchy rashes and uncomfortable plaques finally resolve, patients are often left looking at what dermatologist Tracy Evans, MD, calls a "disfiguring" reminder of the condition. PIH is one of the most treatment-responsive forms of hyperpigmentation, though, and a structured approach — controlling the underlying disease first, then layering in the right actives — can meaningfully shorten the timeline to even skin tone.

Before diving into individual ingredients, here is a side-by-side overview of the main treatment options dermatologists reach for, including their safety profile on already-compromised skin:

Treatment	Mechanism	Best For	Key Risk on Compromised Skin	Typical Strength / Protocol
Hydroquinone (topical)	Inhibits tyrosinase; reduces melanin synthesis	First-line PIH lightening	Ochronosis with prolonged high-dose use; irritation	2–4% Rx; patch-test under chin first
Tretinoin (retinoid)	Accelerates cell turnover; disperses melanin granules	PIH + active psoriasis management	Irritation can trigger more PIH; barrier disruption	Start at 0.025%; lower for sensitive skin
Triple combination cream	Hydroquinone + retinoid + steroid synergy	Moderate-to-severe PIH	Skin atrophy with long-term steroid use	Compounded Rx; dermatologist-guided duration
Azelaic acid	Tyrosinase inhibition; anti-inflammatory	Sensitive or darker skin tones	Very low; well-tolerated	15–20% Rx or 10% OTC
Niacinamide	Blocks melanosome transfer to keratinocytes	Mild PIH; barrier support	Minimal; suitable for reactive skin	4–10% OTC serums
Tranexamic acid	Blocks plasminogen/UV-induced melanogenesis	Stubborn PIH; darker phototypes	Low; emerging evidence	2–5% topical; also oral (Rx)
Broad-spectrum SPF 50+	Prevents UV-driven melanocyte re-stimulation	All PIH patients	None; essential baseline	Daily; tinted with iron oxide preferred
Excimer laser (308 nm)	Targets active psoriasis plaques specifically	Active psoriasis; not PIH directly	Burn risk; may worsen PIH if misused	In-office; skin-type-adjusted dosing
Fraxel / Pico laser	Fractional resurfacing; breaks up dermal pigment	Residual PIH after topicals plateau	High burn risk on darker skin; Koebner risk	In-office; expert-only

What exactly is post-psoriasis hyperpigmentation, and why does it happen?

Post-inflammatory hyperpigmentation is the excess deposition of melanin in the epidermis or dermis following cutaneous inflammation or injury. In psoriasis, the mechanism is more specific than in other inflammatory conditions.

Research from Rockefeller University identified two cytokines that are overactive in psoriasis patients. These cytokines cause melanocytes — the cells responsible for producing skin pigment — to clump together and generate excess melanin. As board-certified dermatologist Ava Shamban, MD, explains, this is a psoriasis-specific mechanism, not simply the generic inflammatory response seen in acne or eczema. Melanin is released into surrounding tissue, and that pigmented layer persists long after the plaque itself has cleared.

The sequence of resolution matters. Dermatologist Shira Y. Wieder, MD, explains that "when you treat psoriasis the scales go away first, then the plaque thins" — it becomes flush with the skin but often remains red, violaceous, or brown depending on the patient's original skin color. After that redness fades, what's left is the PIH. "That's the last thing to resolve," she says.

PIH is not exclusive to psoriasis patients, but those overactive cytokines may make psoriasis patients more prone to it. It also does not happen to everyone — and when it does appear, it typically shows up as flat, non-textured patches rather than raised lesions. Eucerin's dermatological guidance defines PIH as non-textured, flat, discolored patches that manifest after trauma to the skin — a key distinction from scarring, which alters skin texture.

How long does post-psoriasis PIH actually last without treatment?

Left untreated, PIH from psoriasis typically resolves on its own — but the timeline is highly variable. Dermatologists generally quote a range of three months to over a year, and in some cases significantly longer.

A study from an Asian cohort of over 300 patients across seven countries found that PIH lasted longer than one year in 65 percent of patients, and more than five years in 22 percent. That data comes from acne-associated PIH rather than psoriasis specifically, but the underlying biology of melanin persistence is comparable.

Two factors consistently determine how stubborn PIH will be.

Skin tone is the first. PIH occurs more commonly in individuals with darker skin tones, affecting between 45 and 87 percent of patients with Fitzpatrick Skin Types IV, V, and VI. Melanin-rich skin has more melanocytes to begin with, and those melanocytes are more reactive to inflammatory signals. The pigment also tends to sit deeper in the dermis in darker skin types, making it more resistant to topical treatment.

Sun exposure is the second. UV radiation directly stimulates melanocyte activity. Any unprotected sun exposure during the PIH phase can deepen existing patches and create new ones, effectively resetting the clock on resolution. This is why dermatologists treat sun protection not as an adjunct but as a prerequisite.

Dr. Wieder's approach for patients who are not ready to commit to a full treatment protocol is "watchful waiting" — monitoring the patches over time without intervention. That is a valid choice, but for patients with darker skin tones or significant psychosocial impact, active treatment is the more practical path.

Should you treat psoriasis or the hyperpigmentation first?

This question has a clear answer: treat the psoriasis first, always.

"The most important thing is to make sure the active psoriasis is under control because that's where new areas of pigment are going to come from," says Dr. Miller. Attempting to fade existing dark patches while new inflammation is still generating melanin is a losing strategy — you are, as one treatment guide puts it, "fading pigment with one hand and creating it with the other."

The Kallistia treatment framework for PIH makes this point explicitly as Step 1: stop the inflammation that started it. If the source of inflammation is still present, no topical active will outpace it. For psoriasis patients, this means ensuring plaques are fully resolved or well-managed before introducing brightening agents.

There is also a practical reason to sequence treatments this way: many of the actives used for PIH — particularly retinoids and hydroquinone — can be irritating, and applying them to skin that is still inflamed or barrier-compromised from active psoriasis risks worsening the condition or triggering the Koebner phenomenon (new psoriasis lesions appearing at sites of skin trauma).

Both Dr. Shamban and Dr. Evans emphasize that aggressive treatment of psoriasis itself — particularly oral or injectable biologics — can reduce PIH risk by clearing plaques faster. "If you can limit the inflammation, then you can, hopefully, limit the hyperpigmentation," Dr. Evans explains. The faster and more completely psoriasis resolves, the less residual melanin deposition occurs.

Which brightening actives are safe for post-psoriasis skin?

Once psoriasis is under control, dermatologists reach for a fairly consistent toolkit of brightening actives. The key principle on already-compromised skin is to start low, go slow, and monitor for irritation — because any new inflammation can restart the PIH cycle.

Hydroquinone

Hydroquinone is a topical depigmenting agent that works by inhibiting tyrosinase, the enzyme responsible for converting tyrosine to melanin. It remains the most commonly used first-line treatment for PIH. Dr. Miller calls hydroquinone-based brighteners "really the first line to try to lighten pigmentation" in psoriasis patients.

Strength matters significantly. Over-the-counter formulations are typically 2%, while prescription versions range from 3–4% and compounded creams can go higher. Dr. Wieder warns against accidentally using very high-potency hydroquinone, which can cause ochronosis — a permanent darkening of the skin. This risk is not theoretical: a systematic review found that most cases of hydroquinone-induced ochronosis occurred in women with Fitzpatrick Skin Types V and VI, with 35.7% of affected patients using concentrations greater than 4%.

Dr. Wieder's protocol: patch-test under the chin before applying to the face, and adjust the percentage based on how long treatment is planned, whether the condition is recurrent, and how sensitive the patient's skin is. Hydroquinone is generally not recommended for continuous use beyond three to four months without a break.

Retinoids

Retinoids — including tretinoin (prescription) and retinol (OTC) — work by accelerating epidermal cell turnover, which helps shed pigmented cells faster and disperses melanin granules more evenly. They are also independently effective for managing psoriasis, making them a dual-purpose option.

Dr. Wieder notes that tretinoin "has been shown to help with the post-inflammatory hyperpigmentation," but cautions that "tretinoin and even hydroquinone can be irritating," which could lead to more PIH. For sensitive or compromised skin, she recommends starting at 0.025% tretinoin — the lowest available prescription strength. Some insurance plans will cover compounds at this concentration, which can offset cost.

A post-hoc analysis of a Phase III study found significant decreases in hyperpigmentation after 12 weeks of tazarotene 0.045% lotion in patients of African descent and Hispanic ethnicity, suggesting retinoids can be effective across skin tones when used appropriately.

Triple combination cream (compounded)

When multiple actives are warranted, dermatologists often prescribe a compounded cream combining hydroquinone, a retinoid, and a low-potency corticosteroid. Dr. Evans notes that "a brightening agent that has the steroid combined with the hydroquinone and the retinoid is actually helpful for both the psoriasis and the hyperpigmentation". Dr. Miller agrees that these ingredients tend to work better in combination than individually.

The steroid component serves two purposes: it reduces residual inflammation and helps counteract the irritation that retinoids and hydroquinone can cause. Long-term topical steroid use carries its own risks, though — including skin atrophy and potential worsening of psoriasis on withdrawal — so these compounded creams are typically used for defined treatment cycles rather than indefinitely.

Azelaic acid

Azelaic acid is a dicarboxylic acid derived from grains that inhibits tyrosinase activity and has direct anti-inflammatory properties. It is particularly well-suited for post-psoriasis skin because it addresses both residual inflammation and pigmentation simultaneously, with a very low irritation profile.

A nationwide survey of 409 Indian dermatologists found that azelaic acid was used as a second-line agent by 30.9% of respondents for hyperpigmentation management, and it ranked among the most accepted newer depigmenting agents in clinical practice. Its tolerability makes it a strong option for patients with reactive or barrier-compromised skin who cannot tolerate hydroquinone or retinoids at standard concentrations.

Niacinamide and tranexamic acid

These two newer actives have gained significant traction in PIH management, particularly for patients with darker skin tones or sensitivity concerns.

Niacinamide (vitamin B3) works by blocking the transfer of melanosomes from melanocytes to keratinocytes — interrupting the pigmentation process without inhibiting melanin synthesis directly. This mechanism makes it very well-tolerated, with minimal irritation risk even on compromised skin. The Indian dermatologist survey found niacinamide was among the most accepted newer depigmenting agents, cited by 21.9% of respondents.

Tranexamic acid, also cited by 21.9% of surveyed dermatologists, works by blocking the interaction between keratinocytes and melanocytes that UV exposure triggers. It is available both topically (2–5%) and orally by prescription, with a favorable safety profile and growing use for stubborn PIH that has not responded adequately to first-line agents.

How important is sun protection, and what kind should you use?

Sun protection is not optional in post-psoriasis PIH management — it is the single factor that most determines whether any other treatment will work.

As Dr. Evans explains, "hyperpigmentation is pigmented skin. All pigmented skin likes to get more pigmented with the sun, so keeping out of sunlight is helpful to prevent it from getting worse." UV radiation directly stimulates melanocytes, which means unprotected sun exposure actively undermines every brightening active you apply.

The Indian dermatologist survey found that poor sun protection was the most commonly cited reason for hyperpigmentation relapse, identified by 34.7% of respondents — ahead of treatment non-compliance (32.8%). The recommended sunscreen type in that survey: broad-spectrum SPF 50+, PA++++, tinted formulas (preferred by 60.2% of dermatologists), followed by non-tinted broad-spectrum SPF 50+ (35.2%).

Tinted sunscreens with iron oxide are particularly valuable for PIH patients because iron oxide provides protection against visible light, which can also stimulate melanocyte activity — a factor that standard chemical or mineral sunscreens do not fully address.

Dr. Miller's clinical approach goes further: he schedules hyperpigmentation treatment during low-sun-exposure periods — like mid-winter — and explicitly advises patients to avoid natural sunlight where possible during the treatment window. Physical barriers (wide-brim hats, shade-seeking behavior) complement sunscreen, particularly for patients who spend significant time outdoors.

What about in-office treatments — are lasers safe for post-psoriasis skin?

In-office procedures can be effective when topical treatments have plateaued, but they require careful selection and expert administration — particularly for patients with darker skin tones or a history of Koebner phenomenon (new psoriasis lesions triggered by skin trauma).

Excimer laser (308 nm)

The excimer laser is the primary light-based treatment used for active psoriasis. Dr. Wieder clarifies that "that laser does not help the discoloration that a plaque of psoriasis leaves, but truly treats the psoriasis only" — meaning it addresses the underlying disease rather than residual PIH. By clearing psoriasis more rapidly, though, it can indirectly reduce PIH risk.

Kayakalp Global's phototherapy guidance for Indian skin types IV–VI notes that targeted excimer laser (308 nm) is particularly useful for localized patches because it treats only the affected plaque, preventing surrounding healthy skin from tanning — a meaningful advantage over full-body phototherapy chambers for patients concerned about uneven pigmentation.

Fraxel and pico lasers

For residual PIH that has not responded to topicals, Dr. Evans uses Fraxel or pico lasers. "You have to be careful. You don't want to damage the skin — you want to stimulate it," she says. These fractional and ultra-short-pulse devices break up dermal pigment deposits without ablating the full skin surface, reducing downtime and trauma risk.

The critical caveat: Dr. Miller emphasizes the need for caution with light-based therapies "especially with patients with darker skin types, to make sure we don't make these processes worse". He recommends starting with the most gentle, mild procedures and escalating only if needed. Dr. Wieder adds that any laser used incorrectly carries a burn risk that could worsen psoriasis or trigger new plaques.

In-office treatments are a legitimate escalation option, but only under the care of a board-certified dermatologist with specific experience treating psoriasis patients. Disclosing recent sun exposure, skin trauma, or active psoriasis activity before any procedure is essential.

Are there special considerations for darker skin tones?

Yes — and this is an area where the standard advice for PIH management needs meaningful nuance.

PIH occurs more commonly and more severely in individuals with higher Fitzpatrick skin types. The Journal of Clinical and Aesthetic Dermatology reports PIH occurs in 45–87% of patients with Fitzpatrick Skin Types IV, V, and VI, compared to lower rates in lighter skin tones. The pigment also tends to deposit more deeply in the dermis in darker skin, making it more resistant to topical treatment and more prone to persisting for years.

Several specific risks apply to darker skin patients.

Hydroquinone-induced ochronosis, as noted above, is concentrated in patients with Fitzpatrick Types V and VI. Keeping concentrations at or below 4%, limiting continuous use duration, and monitoring for early signs — bluish-grey discoloration in treated areas — are essential safeguards.

Laser-induced PIH is another concern. Aggressive laser settings on melanin-rich skin can cause thermal injury that triggers a new round of PIH — or, in psoriasis patients, new plaques via the Koebner phenomenon. Starting with the most conservative settings and longer intervals between sessions is standard practice.

Phototherapy tanning is a third issue. Kayakalp Global's guide notes that Indian patients undergoing phototherapy commonly experience a "phototherapy tan" — a darkening of treated areas that can be aesthetically distressing even as the psoriasis itself improves. Managing this requires individualized dosing, slower dose escalation, and post-session skincare including intensive moisturizers to repair the skin barrier.

For Fitzpatrick Types IV–VI, azelaic acid, niacinamide, and tranexamic acid are generally considered safer first-line options than high-concentration hydroquinone or aggressive retinoid protocols, because their mechanisms do not depend on irritating concentrations and their side-effect profiles are more favorable.

What does a practical at-home routine look like?

Putting the clinical guidance together into a daily routine, the structure looks like this:

Morning:

Gentle, non-stripping cleanser (fragrance-free, pH-balanced)
Niacinamide serum (4–10%) or tranexamic acid serum (2–5%) — apply to PIH areas
Moisturizer to support barrier function (especially important on post-psoriasis skin)
Broad-spectrum SPF 50+ sunscreen, tinted with iron oxide if possible; reapply every two hours during outdoor exposure

Evening:

Gentle cleanser
Hydroquinone cream (if prescribed) or azelaic acid — apply to PIH areas only
Retinoid (0.025% tretinoin or OTC retinol equivalent) — if tolerated; start 2–3 nights per week and increase gradually
Moisturizer

A few practical notes: introduce one new active at a time, waiting at least two weeks between additions to identify any irritation triggers. If redness, stinging, or new inflammation appears, pull back to the last tolerated step. Patch-testing under the chin before applying any new active to the face — as Dr. Wieder recommends — is a low-effort safeguard that can prevent significant setbacks.

The CTMP regimen (Cleanse, Treat, Moisturize, Protect) was followed by 86.3% of dermatologists in the Indian nationwide survey, reflecting broad clinical consensus that moisturization and photoprotection are not optional add-ons but structural pillars of any PIH treatment plan.

How can you reduce the risk of PIH developing in the first place?

There is no guaranteed way to prevent post-psoriasis PIH, but the evidence points clearly toward two strategies that reduce risk.

Treating psoriasis early and aggressively is the first. The faster plaques resolve, the less cumulative inflammation drives melanocyte activity. Oral and injectable biologics — which clear psoriasis more rapidly than topical-only approaches — appear to reduce PIH incidence by limiting the duration of inflammatory signaling. "If you can limit the inflammation, then you can, hopefully, limit the hyperpigmentation," Dr. Evans explains.

Starting sun protection before PIH appears is the second. Areas showing early signs of inflammation — redness, texture change, itching — have the potential to become hyperpigmented once psoriasis resolves. Applying sunscreen to those areas proactively, before the plaque fully clears, can reduce the degree of pigmentation that develops. Dr. Miller advises patients to start sun protection as soon as they notice an area that "looks like it might pigment."

Avoiding skin trauma in psoriasis-prone areas is also worth noting: scratching, picking, or aggressive exfoliation can both worsen active psoriasis via Koebner and increase PIH risk in areas that are healing.

When should you see a dermatologist rather than self-treating?

Self-treatment with OTC actives is reasonable for mild, superficial PIH in patients with lighter skin tones who have well-controlled psoriasis. Several situations call for professional guidance, though:

PIH that has persisted for more than six months without improvement
Darker skin tones (Fitzpatrick Types IV–VI), where the risk of treatment-induced complications is higher
Uncertainty about whether patches represent PIH, active psoriasis, or ochronosis — all of which can look similar to the untrained eye
Interest in prescription-strength hydroquinone, tretinoin, or compounded triple-combination creams
Consideration of any laser or light-based procedure

Dr. Evans emphasizes that hyperpigmentation "is a medical issue and should be treated" — not dismissed as purely cosmetic. The psychological burden is real, and effective treatment exists. The key is matching the treatment to the skin, not applying a one-size-fits-all protocol to skin that has already been through significant inflammatory stress.